Company: SXTPW
Filing Date: 2025-07-18
Form Type: 8-K
Source: 0001213900-25-065718
Chunk: 0

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-07-18
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01. Entry into a Material Definitive
Agreement.

On July 15, 2025, 60 Degrees Pharmaceuticals,
Inc. (the “ Company”) entered into a Securities Purchase Agreement (the “ Purchase Agreement”) with certain institutional
investors (the “ Investors”) relating to the sale of (i) 1,753,314 share of the Company’s common stock, par value $0.0001
per share (the “ Common Stock”), (ii) 878,264 pre-funded warrants (the “ Pre-Funded Warrants”) to purchase up to
878,264 shares of Common Stock, (iii) Series A-1 warrants to purchase up to 878,264 shares of Common Stock (the “ Series A-1 Warrants”),
and (iv) Series A-2 warrants to purchase up to 878,264 shares of Common Stock (the “ Series A-2 Warrants”, and together with
the Series A-1 Warrants, the “ Warrants”) in a best efforts follow-on offering (the “ Offering”). In addition, the
Company is issuing placement agent warrants (the “ Placement Agent Warrants”) to purchase a total of 197,368 shares of Common
Stock (the “ Placement Agent Warrant Shares”).

The combined offering price per share of Common
Stock and accompanying Warrants was $1.90, and the combined offering price per Pre-Funded Warrant and accompanying Warrants was $1.899.

The Offering closed on July 16, 2025. The gross
proceeds from the Offering were approximately $5.0 million, before deducting placement agent fees and other offering expenses payable
by the Company. The Company intends to use the net proceeds from the Offering for general corporate purposes, including working capital.

The Offering was made pursuant to the Company’s
registration statement on Form S-1 (File No. 333-288550), which was declared effective by the Securities and Exchange Commission (the
“ SEC”) on July 15, 2025, and the final prospectus, which was filed with the SEC on July 16, 2025.

The Purchase Agreement contains customary representations,
warranties and covenants by the Company, and customary conditions to closing. The foregoing description of the Purchase Agreement and
the Warrants is not complete and is qualified in its entirety by reference to the full text of such documents, copies of which will be
filed as exhibits to the Company